Do analysts recommend DMAA or APPS?

Digital Turbine has a consensus price target of $11.00, indicating a potential upside of 30.18%. Given Digital Turbine's stronger consensus rating and higher possible upside, analysts plainly believe Digital Turbine is more favorable than Drugs Made In America Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Drugs Made In America Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Digital Turbine 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has stronger valuation & earnings, DMAA or APPS?

Drugs Made In America Acquisition has higher earnings, but lower revenue than Digital Turbine. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Drugs Made In America Acquisition N/A N/A N/A N/A N/A Digital Turbine $565.25M 1.81 -$37.73M -$0.36 N/A

Does the media refer more to DMAA or APPS?

In the previous week, Digital Turbine had 13 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 15 mentions for Digital Turbine and 2 mentions for Drugs Made In America Acquisition. Drugs Made In America Acquisition's average media sentiment score of 1.64 beat Digital Turbine's score of 0.85 indicating that Drugs Made In America Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Drugs Made In America Acquisition 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Digital Turbine 5 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer DMAA or ABR?

Arbor Realty Trust has a consensus price target of $6.50, suggesting a potential upside of 29.87%. Given Arbor Realty Trust's stronger consensus rating and higher possible upside, analysts clearly believe Arbor Realty Trust is more favorable than Drugs Made In America Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Drugs Made In America Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Arbor Realty Trust 4 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger earnings & valuation, DMAA or ABR?

Arbor Realty Trust has higher revenue and earnings than Drugs Made In America Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Drugs Made In America Acquisition N/A N/A N/A N/A N/A Arbor Realty Trust $940.01M 1.02 $148.80M $0.39 12.83

Does the media favor DMAA or ABR?

In the previous week, Arbor Realty Trust had 4 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 6 mentions for Arbor Realty Trust and 2 mentions for Drugs Made In America Acquisition. Drugs Made In America Acquisition's average media sentiment score of 1.64 beat Arbor Realty Trust's score of 0.64 indicating that Drugs Made In America Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Drugs Made In America Acquisition 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Arbor Realty Trust 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer DMAA or ESRT?

Empire State Realty Trust has a consensus price target of $5.92, indicating a potential upside of 4.39%. Given Empire State Realty Trust's stronger consensus rating and higher probable upside, analysts plainly believe Empire State Realty Trust is more favorable than Drugs Made In America Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Drugs Made In America Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Empire State Realty Trust 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33

Which has stronger valuation and earnings, DMAA or ESRT?

Empire State Realty Trust has higher revenue and earnings than Drugs Made In America Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Drugs Made In America Acquisition N/A N/A N/A N/A N/A Empire State Realty Trust $768.27M 1.27 $47.60M $0.26 21.80

Do analysts rate DMAA or ABX?

Abacus Global Management has a consensus target price of $13.00, indicating a potential upside of 25.24%. Given Abacus Global Management's stronger consensus rating and higher possible upside, analysts plainly believe Abacus Global Management is more favorable than Drugs Made In America Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Drugs Made In America Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Abacus Global Management 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher earnings and valuation, DMAA or ABX?

Abacus Global Management has higher revenue and earnings than Drugs Made In America Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Drugs Made In America Acquisition N/A N/A N/A N/A N/A Abacus Global Management $235.24M 4.23 $36.53M $0.39 26.62

Does the media prefer DMAA or ABX?

In the previous week, Drugs Made In America Acquisition and Drugs Made In America Acquisition both had 2 articles in the media. Drugs Made In America Acquisition's average media sentiment score of 1.64 beat Abacus Global Management's score of 0.68 indicating that Drugs Made In America Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Drugs Made In America Acquisition 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Abacus Global Management 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RPC or DMAA?

Ridgepost Capital presently has a consensus price target of $12.00, indicating a potential upside of 42.42%. Given Ridgepost Capital's stronger consensus rating and higher probable upside, analysts plainly believe Ridgepost Capital is more favorable than Drugs Made In America Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ridgepost Capital 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Drugs Made In America Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, RPC or DMAA?

Ridgepost Capital has higher revenue and earnings than Drugs Made In America Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ridgepost Capital $297.35M 3.10 $19.50M $0.22 38.30 Drugs Made In America Acquisition N/A N/A N/A N/A N/A

Drugs Made In America Acquisition (DMAA) Competitors

$10.70 +0.02 (+0.14%)

Closing price 07/24/2026 03:56 PM Eastern

Extended Trading

$10.69 -0.02 (-0.14%)

As of 07/24/2026 04:04 PM Eastern

Compare

DMAA vs. APPS, ABR, ESRT, ABX, and RPC

Should you buy Drugs Made In America Acquisition stock or one of its competitors? MarketBeat compares Drugs Made In America Acquisition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Drugs Made In America Acquisition include Digital Turbine (APPS), Arbor Realty Trust (ABR), Empire State Realty Trust (ESRT), Abacus Global Management (ABX), and Ridgepost Capital (RPC). These companies are all part of the "trading" industry.

How does Drugs Made In America Acquisition compare to Digital Turbine?

Drugs Made In America Acquisition (NASDAQ:DMAA) and Digital Turbine (NASDAQ:APPS) are both small-cap trading companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

In the previous week, Digital Turbine had 13 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 15 mentions for Digital Turbine and 2 mentions for Drugs Made In America Acquisition. Drugs Made In America Acquisition's average media sentiment score of 1.64 beat Digital Turbine's score of 0.85 indicating that Drugs Made In America Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Drugs Made In America Acquisition	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Digital Turbine	5 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Drugs Made In America Acquisition has higher earnings, but lower revenue than Digital Turbine.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A
Digital Turbine	$565.25M	1.81	-$37.73M	-$0.36	N/A

Drugs Made In America Acquisition has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market. Comparatively, Digital Turbine has a beta of 2.75, meaning that its share price is 175% more volatile than the broader market.

Drugs Made In America Acquisition has a net margin of 0.00% compared to Digital Turbine's net margin of -6.68%. Digital Turbine's return on equity of 27.60% beat Drugs Made In America Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Drugs Made In America Acquisition	N/A	N/A	N/A
Digital Turbine	-6.68%	27.60%	5.68%

Digital Turbine has a consensus price target of $11.00, indicating a potential upside of 30.18%. Given Digital Turbine's stronger consensus rating and higher possible upside, analysts plainly believe Digital Turbine is more favorable than Drugs Made In America Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Digital Turbine	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

63.7% of Digital Turbine shares are owned by institutional investors. 0.9% of Drugs Made In America Acquisition shares are owned by company insiders. Comparatively, 6.0% of Digital Turbine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Digital Turbine beats Drugs Made In America Acquisition on 11 of the 13 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Arbor Realty Trust?

Drugs Made In America Acquisition (NASDAQ:DMAA) and Arbor Realty Trust (NYSE:ABR) are both small-cap trading companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Arbor Realty Trust had 4 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 6 mentions for Arbor Realty Trust and 2 mentions for Drugs Made In America Acquisition. Drugs Made In America Acquisition's average media sentiment score of 1.64 beat Arbor Realty Trust's score of 0.64 indicating that Drugs Made In America Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Drugs Made In America Acquisition	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Arbor Realty Trust	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

57.3% of Arbor Realty Trust shares are owned by institutional investors. 0.9% of Drugs Made In America Acquisition shares are owned by insiders. Comparatively, 4.2% of Arbor Realty Trust shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Arbor Realty Trust has a consensus price target of $6.50, suggesting a potential upside of 29.87%. Given Arbor Realty Trust's stronger consensus rating and higher possible upside, analysts clearly believe Arbor Realty Trust is more favorable than Drugs Made In America Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Arbor Realty Trust	4 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.50

Arbor Realty Trust has a net margin of 12.73% compared to Drugs Made In America Acquisition's net margin of 0.00%. Arbor Realty Trust's return on equity of 8.49% beat Drugs Made In America Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Drugs Made In America Acquisition	N/A	N/A	N/A
Arbor Realty Trust	12.73%	8.49%	1.46%

Drugs Made In America Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, Arbor Realty Trust has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

Arbor Realty Trust has higher revenue and earnings than Drugs Made In America Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A
Arbor Realty Trust	$940.01M	1.02	$148.80M	$0.39	12.83

Summary

Arbor Realty Trust beats Drugs Made In America Acquisition on 11 of the 12 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Empire State Realty Trust?

Drugs Made In America Acquisition (NASDAQ:DMAA) and Empire State Realty Trust (NYSE:ESRT) are both small-cap trading companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

In the previous week, Empire State Realty Trust had 5 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 7 mentions for Empire State Realty Trust and 2 mentions for Drugs Made In America Acquisition. Drugs Made In America Acquisition's average media sentiment score of 1.64 beat Empire State Realty Trust's score of 0.90 indicating that Drugs Made In America Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Drugs Made In America Acquisition	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Empire State Realty Trust	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.1% of Empire State Realty Trust shares are held by institutional investors. 0.9% of Drugs Made In America Acquisition shares are held by insiders. Comparatively, 15.2% of Empire State Realty Trust shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Empire State Realty Trust has higher revenue and earnings than Drugs Made In America Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A
Empire State Realty Trust	$768.27M	1.27	$47.60M	$0.26	21.80

Empire State Realty Trust has a net margin of 5.09% compared to Drugs Made In America Acquisition's net margin of 0.00%. Empire State Realty Trust's return on equity of 2.19% beat Drugs Made In America Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Drugs Made In America Acquisition	N/A	N/A	N/A
Empire State Realty Trust	5.09%	2.19%	0.93%

Drugs Made In America Acquisition has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, Empire State Realty Trust has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

Empire State Realty Trust has a consensus price target of $5.92, indicating a potential upside of 4.39%. Given Empire State Realty Trust's stronger consensus rating and higher probable upside, analysts plainly believe Empire State Realty Trust is more favorable than Drugs Made In America Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Empire State Realty Trust	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

Summary

Empire State Realty Trust beats Drugs Made In America Acquisition on 10 of the 11 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Abacus Global Management?

Drugs Made In America Acquisition (NASDAQ:DMAA) and Abacus Global Management (NYSE:ABX) are both small-cap financial services companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

Drugs Made In America Acquisition has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market. Comparatively, Abacus Global Management has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market.

Abacus Global Management has a consensus target price of $13.00, indicating a potential upside of 25.24%. Given Abacus Global Management's stronger consensus rating and higher possible upside, analysts plainly believe Abacus Global Management is more favorable than Drugs Made In America Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Abacus Global Management	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Abacus Global Management has a net margin of 15.63% compared to Drugs Made In America Acquisition's net margin of 0.00%. Abacus Global Management's return on equity of 20.02% beat Drugs Made In America Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Drugs Made In America Acquisition	N/A	N/A	N/A
Abacus Global Management	15.63%	20.02%	9.65%

Abacus Global Management has higher revenue and earnings than Drugs Made In America Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A
Abacus Global Management	$235.24M	4.23	$36.53M	$0.39	26.62

In the previous week, Drugs Made In America Acquisition and Drugs Made In America Acquisition both had 2 articles in the media. Drugs Made In America Acquisition's average media sentiment score of 1.64 beat Abacus Global Management's score of 0.68 indicating that Drugs Made In America Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Drugs Made In America Acquisition	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Abacus Global Management	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Abacus Global Management beats Drugs Made In America Acquisition on 8 of the 9 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Ridgepost Capital?

Ridgepost Capital (NYSE:RPC) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap financial services companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Ridgepost Capital has a net margin of 7.99% compared to Drugs Made In America Acquisition's net margin of 0.00%. Ridgepost Capital's return on equity of 24.58% beat Drugs Made In America Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ridgepost Capital	7.99%	24.58%	10.56%
Drugs Made In America Acquisition	N/A	N/A	N/A

Ridgepost Capital presently has a consensus price target of $12.00, indicating a potential upside of 42.42%. Given Ridgepost Capital's stronger consensus rating and higher probable upside, analysts plainly believe Ridgepost Capital is more favorable than Drugs Made In America Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ridgepost Capital	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Drugs Made In America Acquisition had 1 more articles in the media than Ridgepost Capital. MarketBeat recorded 2 mentions for Drugs Made In America Acquisition and 1 mentions for Ridgepost Capital. Drugs Made In America Acquisition's average media sentiment score of 1.64 beat Ridgepost Capital's score of 0.50 indicating that Drugs Made In America Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ridgepost Capital	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Drugs Made In America Acquisition	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

48.1% of Ridgepost Capital shares are owned by institutional investors. 11.8% of Ridgepost Capital shares are owned by company insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Ridgepost Capital has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market.

Ridgepost Capital has higher revenue and earnings than Drugs Made In America Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ridgepost Capital	$297.35M	3.10	$19.50M	$0.22	38.30
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Ridgepost Capital beats Drugs Made In America Acquisition on 10 of the 12 factors compared between the two stocks.

Get Drugs Made In America Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMAA vs. The Competition

Export

Metric	Drugs Made In America Acquisition	Investment Offices Industry	Financial Sector	NASDAQ Exchange
Market Cap	$259.76M	$291.30M	$5.52B	$12.20B
Dividend Yield	N/A	N/A	5.26%	9.41%
P/E Ratio	N/A	2.08	29.39	23.62
Price / Sales	N/A	147.90	1,138.31	89.60
Price / Cash	N/A	135.00	114.00	58.78
Price / Book	N/A	353.11	6.68	6.01
Net Income	N/A	-$66.54M	$1.13B	$331.99M
7 Day Performance	0.33%	-0.34%	-0.46%	-0.63%
1 Month Performance	0.61%	-1.26%	-0.18%	-3.04%
1 Year Performance	4.24%	2.17%	13.15%	13.30%

Drugs Made In America Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMAA Drugs Made In America Acquisition	0.882 of 5 stars	$10.71 +0.1%	N/A	+4.2%	$259.76M	N/A	N/A	2	Positive News
APPS Digital Turbine	4.4347 of 5 stars	$8.34 -3.4%	$8.75 +4.9%	+54.8%	$1.01B	$565.25M	N/A	840	News Coverage Analyst Forecast Gap Down
ABR Arbor Realty Trust	4.4133 of 5 stars	$5.17 +0.3%	$6.50 +25.8%	-58.5%	$996.43M	$940.01M	13.24	630
ESRT Empire State Realty Trust	1.8982 of 5 stars	$5.78 +0.4%	$5.92 +2.5%	-23.7%	$994.92M	$768.27M	22.21	670	News Coverage Positive News Upcoming Earnings
ABX Abacus Global Management	3.4122 of 5 stars	$10.33 -1.7%	$13.00 +25.8%	N/A	$993.75M	$235.24M	26.49	82

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMAA) was last updated on 7/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Drugs Made In America Acquisition (DMAA) Competitors

DMAA vs. APPS, ABR, ESRT, ABX, and RPC

How does Drugs Made In America Acquisition compare to Digital Turbine?

Summary

How does Drugs Made In America Acquisition compare to Arbor Realty Trust?

Summary

How does Drugs Made In America Acquisition compare to Empire State Realty Trust?

Summary

How does Drugs Made In America Acquisition compare to Abacus Global Management?

Summary

How does Drugs Made In America Acquisition compare to Ridgepost Capital?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAA vs. The Competition

Drugs Made In America Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Drugs Made In America Acquisition (DMAA) Competitors

DMAA vs. APPS, ABR, ESRT, ABX, and RPC

How does Drugs Made In America Acquisition compare to Digital Turbine?

Does the media refer more to DMAA or APPS?

Which has stronger valuation & earnings, DMAA or APPS?

Which has more risk and volatility, DMAA or APPS?

Is DMAA or APPS more profitable?

Do analysts recommend DMAA or APPS?

Do insiders and institutionals have more ownership in DMAA or APPS?

Summary

How does Drugs Made In America Acquisition compare to Arbor Realty Trust?

Does the media favor DMAA or ABR?

Do institutionals and insiders have more ownership in DMAA or ABR?

Do analysts prefer DMAA or ABR?

Is DMAA or ABR more profitable?

Which has more risk & volatility, DMAA or ABR?

Which has stronger earnings & valuation, DMAA or ABR?

Summary

How does Drugs Made In America Acquisition compare to Empire State Realty Trust?

Does the media favor DMAA or ESRT?

Do insiders and institutionals believe in DMAA or ESRT?

Which has stronger valuation and earnings, DMAA or ESRT?

Is DMAA or ESRT more profitable?

Which has more volatility & risk, DMAA or ESRT?

Do analysts prefer DMAA or ESRT?

Summary

How does Drugs Made In America Acquisition compare to Abacus Global Management?

Which has more volatility & risk, DMAA or ABX?

Do analysts rate DMAA or ABX?

Is DMAA or ABX more profitable?

Which has higher earnings and valuation, DMAA or ABX?

Does the media prefer DMAA or ABX?

Summary

How does Drugs Made In America Acquisition compare to Ridgepost Capital?

Is RPC or DMAA more profitable?

Do analysts rate RPC or DMAA?

Does the media refer more to RPC or DMAA?

Do institutionals and insiders believe in RPC or DMAA?

Which has more risk and volatility, RPC or DMAA?

Which has preferable valuation and earnings, RPC or DMAA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAA vs. The Competition

Drugs Made In America Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools